OBJECTIVES:Acid-reducing agents (ARAs) and proton-pump inhibitors (PPIs) that increase gastric pH can alter the bioavailability of antiviral drugs, particularly relevant in patients with advanced liver disease caused by chronic hepatitis C virus (HCV) infection seeking therapy. Using integrated data from six phase 3 studies, we report the safety and efficacy of the 3-direct-acting antiviral (DAA) regimen containing ombitasvir (OBV, an NS5A inhibitor), ritonavir-boosted paritaprevir (PTV/r, an NS3/4A protease inhibitor), and dasabuvir (DSV, an NS5B polymerase inhibitor) with or without ribavirin (RBV) for HCV genotype 1 patients taking concomitant ARAs and PPIs.METHODS:Treatment-naïve or peginterferon/RBV treatment-experienced patients with or without compensated cirrhosis received OBV/PTV/r and DSV with or without weight-based RBV. Rates of sustained virologic response (SVR), defined as HCV RNA below the lower limit of quantification, 12 weeks post-treatment (SVR12) and safety were evaluated in patients who were receiving concomitant ARAs.RESULTS:Among 2,053 patients enrolled and dosed with study drug, 410 (20%) were receiving concomitant ARAs; of these, 308 (15%) were taking concomitant PPIs. Rates of SVR12 were 95.9% (95% confidence interval (CI) 93.5–97.4%) among patients receiving an ARA, and 96.3% (95% CI 95.3–97.2%) in patients not receiving a concomitant ARA. Similarly, among patients receiving a PPI or not, SVR12 was achieved in 95.1% (95% CI 92.1–97.0%) and 96.4% (95% CI 95.5–97.2%), respectively. Response rates were high regardless of treatment regimen (with or without RBV), and among patients receiving a standard or high dose of PPIs. Regarding safety, adverse events and serious adverse events were more frequently reported in patients taking concomitant ARAs, though baseline population differences may have played a role.CONCLUSIONS:In phase 3 trials of OBV/PTV/r plus DSV and RBV in HCV genotype 1-infected patients, SVR12 rates were high regardless of ARA/PPI use or PPI dose. These data support the co-administration of this regimen with ARAs including PPIs.
genotype            1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Genotype              

phase 3                       0.9999999741453397^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Clinical_trial        

infection                     1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Infection             

proton-pump inhibitors        1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Proton-pump_inhibitor 

HCV                           1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Hepatitis_C_virus     

cirrhosis                     1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Cirrhosis             

adverse events                0.9999999687777295^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Adverse_effect        

95% CI                        1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Confidence_interval   

bioavailability               1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Bioavailability       

NS5A                          1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/NS5A                  

NS3                           1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/NS3_(HCV)             

HCV                           1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Hepatitis_C_virus     

95% CI                        1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Confidence_interval   

ARAs                          0.999997522781881^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Aras_River            

drug                          0.9593029322433297^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Pharmaceutical_drug   

PPI                           1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Proton-pump_inhibitor 

quantification                0.9756487888568275^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Level_of_measurement  

liver disease                 0.9997961521734152^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Liver                 

ARAs                          0.999997522781881^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Aras_River            

95% CI                        1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Confidence_interval   

adverse events                0.9999999687777295^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Adverse_effect        

DSV                           0.7111484937480541^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Verbandsbauart        

efficacy                      1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Efficacy              

polymerase                    0.9580164597262324^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/RNA_polymerase        

antiviral drugs               1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Antiviral_drug        

CI                            1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Confidence_interval   

safety                        0.9999400785675516^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Safety                

ARAs                          0.999997522781881^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Aras_River            

hepatitis                     1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Hepatitis             

HCV                           1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Hepatitis_C_virus     

gastric                       0.579655578566934^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Stomach               

inhibitor                     0.9999999912147359^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Enzyme_inhibitor      

NS5B                          1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/NS5B                  

PTV                           0.7911258181789805^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Pakistan_Television_Corporation

ARA                           0.5628589446142183^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Argentine_Navy        

confidence interval           1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Confidence_interval   

inhibitor                     0.9999999912147359^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Enzyme_inhibitor      

DSV                           0.7111484937480541^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Verbandsbauart        

ARA                           0.5628589446142183^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Argentine_Navy        

PTV                           0.7911258181789805^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Pakistan_Television_Corporation

safety                        0.9999400785675516^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Safety                

HCV                           1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Hepatitis_C_virus     

RNA                           0.994898604557373^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/RNA                   

virus                         1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Virus                 

DAA                           0.8562777812272412^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Dublin_Airport_Authority

SVR                           0.9999999999997726^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Foreign_Intelligence_Service_(Russia)

antiviral                     1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Antiviral_drug        

DSV                           0.7111484937480541^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Verbandsbauart        

PPI                           1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Proton-pump_inhibitor 

phase 3                       0.9999999741453397^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Clinical_trial        

ARAs                          0.999997522781881^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Aras_River            

genotype                      1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Genotype              

pH                            0.9999999999956799^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/PH                    

safety                        0.9999400785675516^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Safety                

PPI                           1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Proton-pump_inhibitor 

protease inhibitor            1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Protease_inhibitor_(pharmacology)

ARAs                          0.999997522781881^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Aras_River            

PTV                           0.7911258181789805^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Pakistan_Television_Corporation

peginterferon                 0.9696331775812579^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/interferon            

ARA                           0.5628589446142183^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Argentine_Navy        

ribavirin                     1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ribavirin             

